24922-01-8

Usage

Uses

Used in Pharmaceutical Industry:
3-Cyclobutyl-3-oxo-propionic acid ethyl ester is used as a building block for the synthesis of various drugs, contributing to the development of new medications and improving existing ones.
Used in Flavor and Fragrance Industry:
3-CYCLOBUTYL-3-OXO-PROPIONIC ACID ETHYL ESTER is also employed as a flavor or fragrance ingredient in various products, enhancing the sensory experience of consumers.
It is crucial to handle 3-Cyclobutyl-3-oxo-propionic acid ethyl ester with care due to its potential to cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C9H14O3/c1-2-12-9(11)6-8(10)7-4-3-5-7/h7H,2-6H2,1H3

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 64-17-5 ethanol 
• 3721-95-7 Cyclobutanecarboxylic acid 
• 6148-64-7 ethyl potassium malonate 
• 3019-25-8 1-cyclobutylethanone 
• 105-58-8 Diethyl carbonate 
• 5006-22-4 Cyclobutanecarbonyl chloride 
• 1071-46-1 hydrogen ethyl malonate 
• 855384-50-8 2-cyclobutanecarbonyl-3-oxo-butyric acid ethyl ester 

Downstream Products

• 1335027-56-9 ethyl 3-cyclobutyl-2-{[4-fluoro-3-(trifluoromethyl)phenyl]methyl}-3-oxopropanoate 
• 1335027-58-1 ethyl 2-[(4-chloro-3-fluoro-phenyl)methyl]-3-cyclobutyl-3-oxo-propanoate 
• 1335027-55-8 ethyl 2-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-3-cyclobutyl-3-oxo-propanoate 
• 1335027-53-6 ethyl 2-[(3-chloro-4-fluorophenyl)methyl]-3-cyclobutyl-3-oxopropanoate 
• 1335027-52-5 ethyl 3-cyclobutyl-2-[(3,4-difluorophenyl)methyl]-3-oxopropanoate 
• 1335027-54-7 ethyl 2-[(3-chlorophenyl)methyl]-3-cyclobutyl-3-oxopropanoate 
• 1335027-51-4 ethyl 3-cyclobutyl-2-[(3,4-dichlorophenyl)methyl]-3-oxopropanoate 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY

Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents

We identified a di-substituted triazolopyrimidine with anti-tubercular activity against Mycobacterium tuberculosis. Three segments of the scaffold were examined rationally to establish a structure-activity relationship with the goal of improving potency and maintaining good physicochemical properties. A number of compounds displayed sub-micromolar activity against Mycobacterium tuberculosis with no cytotoxicity against eukaryotic cells. Non-substituted aromatic rings at C5 and a two-carbon chain connecting a terminal aromatic at C7 were preferred features; the presence of NH at C7 and a lack of substituent at C2 were essential for potency. We identified compounds with acceptable metabolic stability in rodent and human liver microsomes. Our findings suggest that the easily-synthesized triazolopyrimidines are a promising class of potent anti-tubercular agents and warrant further investigation in our search for new drugs to fight tuberculosis.

Synthesis of the 1,3,4-Oxadiazole Core through Thermolysis of Geminal Diazides

The thermolysis of geminal diazides derived from acylacetate compounds is an efficient tool for the rapid construction of the 1,3,4-oxadiazole core. While a broad range of ethyl esters undergoes smooth transformation to the desired heterocycles that contain the ester moiety in moderate to high yields, the analogous tert-butyl esters give rise to the oxadiazoles with acyl groups, presumably through a pathway of decarboxylation followed by a new acyl transfer.

4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS

The present invention relates to novel compounds for use in the compositions, to processes for their preparation, to intermediates useful in their preparation and to their use as therapeutic agents. The present invention also relates to pharmaceutical com

ARYL PYRIMIDINE DERIVATIVES

The disclosed pyrimidine derivatives, and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, in particular use as selective 5HT 2B-antagonists. The invention is also directed to formulations and methods for treatment.

ARYL PYRIMIDINE DERIVATIVES

The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT 2B-antagonists.

ARYL PYRIMIDINE DERIVATIVES AND USES THEREOF

The aryl pyrimidine derivatives and pharmaceutically acceptable salts and N-oxides thereof, exhibit useful pharmacological properties, including utility as selective 5HT 2B-antagonists. The 5-HT 2B antagonist is a compound of the formula: STR1 wherein: R. sup.1 is hydrogen, alkyl, lower alkoxy, hydroxyalkyl, cycloalkyl, cycloalkyl lower alkyl, alkenyl, lower thioalkoxy, halo, fluoroalkyl,--NR 6 R. sup.7,--CO 2 R 8,--O(CH 2) n R 9, or lower alkyl optionally substituted with hydroxy, alkoxy, halo, or aryl; in which n is 1, 2, or 3;R 6 and R 7 are hydrogen or lower alkyl; R 8 is hydrogen or lower alkyl; andR 9 is hydrogen, lower alkyl, hydroxy, hydroxy lower alkyl, lower alkenyl, or lower alkoxy;R. sup.2 is hydrogen, lower alkyl, lower alkoxy, halo, or lower fluoroalkyl; R 3 is optionally substituted aryl other than pyridyl, thienyl, or furanyl;R 4 is hydrogen, lower alkyl, cycloalkyl, alkenyl, acyl, amino, amido, aryl,--(CH 2) m NR. sup.10 R 11, or lower alkyl optionally substituted by amino, monosubstituted amino, disubstituted amino, hydroxy, carboxy, aryl, lower alkoxy, amido, alkoxy carbonyl, tetrahydrofuran-2-yl, hydroxyalkoxy, or sulfonamido;in whichR 10 and R. sup.11 are hydrogen or lower alkyl; andR 5 is hydrogen or lower alkyl; provided that: (i) when R 3 is naphthyl, indol-1-yl, or 2,3-dihydroindol-1-yl, and R 2, R 4 and R 5 are all hydrogen, R. sup.1 is not methyl; (ii) when R 3 is phenyl or naphthyl, R 1 is not--NR 6 R 7 ;(iii) when R 3 is phenyl, R 2 is not lower alkoxy, and R 1 and R 2 are not halo;(iv) when R 3 is phenyl and R 1 is H, R 2 is not methyl; and (v) when R 3 is 1,2,3,4-tetrahydroquinolinyl, R 4 and R. sup.5 are hydrogen;or a pharmaceutically acceptable salt or N-oxide thereof.